The AIM Coalition has provided a response to the Food and Drug Administration’s (FDA) request for comments about its patient-focused drug development initiative.  In its response, AIM thanked the FDA and the Center for Drug Evaluation and Research for including sarcopenia as one of the diseases being considered for a patient-focused drug development meeting for FY 2016-17.  It also encouraged that sarcopenia be prioritized for a meeting due to its impact on the aging population.  You can read the letter here.